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Abstract
Objective
Aims were to investigate sensitivity of various human and canine cancer cell lines to hyper-
thermia and the influence of particular treatment conditions, and to analyze the DNA-dam-
age response and mode of cell death in cell line radiosensitized by hyperthermia.
Additionally, we were interested in the involvement of HSP70 in radiosensitization.
Methods
Radiosensitization by hyperthermia was determined in a panel of human and canine cancer
cell lines using clonogenic cell survival assay, as well as levels of heat shock proteins
(HSPs) using immunoblotting. The influence of the hyperthermia-radiotherapy time gap, dif-
ferent temperatures and the order of treatments on clonogenicity of hyperthermia-sensitive
A549 cells was investigated. Additionally, DNA damage and cell death were assessed by
Comet assay and an apoptosis/necrosis assay. Further we induced transient knockdown in
A549 cells to test HSP70’s involvement in radiosensitization.
Results
Out of eight cell lines tested, only two (A549 and Abrams) showed significant decrease in
clonogenic cell survival when pre-treated with hyperthermia at 42˚C. Strong induction of
HSP70 upon thermoradiotherapy (HT-RT) treatment was found in all cell lines. Transient
knockdown of HSP70 in A549 cells did not result in decrease of clonogenic cell survival in
response to HT-RT.
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Conclusion
Tumor cell-type, temperature and order of treatment play an important role in radiosensitiza-
tion by hyperthermia. However, hyperthermia has limited potency to radiosensitize canine
cancer cells grown in a 2D cell culture setting presented here. DNA damage and apoptosis/
necrosis did not increase upon combined treatment and cytosolic levels of HSP70 appear
not to play critical role in the radiosensitization of A549 cells.
Introduction
Radiotherapy remains one of the major treatment options in human and animal cancer treat-
ment. Unfortunately, due to the intrinsic resistance, many solid tumors are radiation-resistant.
Tumor hypoxia, DNA damage repair capacity and tumor microenvironment are the major
determinants of sensitivity towards radiotherapy.
Pre-treatment of cells with hyperthermia (40±43ÊC) can be used to sensitize tumor tissues
to the subsequent radiotherapy treatment; this concept was described decades ago [1, 2]. The
mechanism of radiosensitization by hyperthermia is multifold and depends on many parame-
ters such as the tumor type or levels of tumor hypoxia. Hyperthermia induces the cellular and
tumor microenvironment changes, which can alter the response to radiotherapy. Acting on
both, tumor microenvironment and cellular level, hyperthermia has been shown to reduce
tumor hypoxia by increasing perfusion [3]. The effects of hyperthermia on tumor perfusion
and oxygenation status have been well characterized [4]. On the other hand, the direct effects
of thermoradiotherapy (perfusion- and hypoxia-independent) on tumor cells alone are yet to
be fully elucidated. Both, the cellular and microenvironment-related effects of hyperthermia
are mediated, among others factors, by heat shock proteins (HSPs). HSPs are molecular chap-
erones induced in response to stresses such as heat, their major function is to help the cell to
adapt to stress conditions and to properly respond to the second stress insult [5]. There are
several members of the heat shock protein family including HSP27, HSP70 and HSP90 being
the best characterized. Their protein levels have been shown to be induced in many malignan-
cies, such as prostate, colorectal carcinoma and ovarian cancer [6]. The role of HSPs proteins
in radio-modulating the effect of hyperthermia is multifold. On one hand, they contribute to
treatment resistance by helping the cell to adapt to stress conditions and on the other hand
they contribute to the immune response to the tumor, which can be complementary to radio-
therapy treatment [7]. Inhibitors of HSP70 and HSP90 have been reported to have antiproli-
ferative and cytotoxic effect on different cancer cell types, including canine osteosarcoma [8].
Moreover, it has been shown that the knockout of HSP70 (HSP70.1 and HSP70.3, mouse
HSP70) in mice resulted in genomic instability, suggesting that HSP70 might play a role in the
DNA damage response, which is one of the main factors responsible for the response to radio-
therapy [9]. Inhibition of HSP70 expression by siRNA has been shown to be cytotoxic in dif-
ferent types of tumor but not in normal tissue [6].
The aim of our study was twofold. First, to screen the human and canine cancer cell lines
for their sensitivity towards hyperthermia-radiotherapy treatment using clonogenic cell sur-
vival assay as a read-out and to analyze the effect of thermoradiotherapy on DNA damage, and
apoptosis/necrosis [10]. Second, to investigate the role of HSP70 protein in mechanism of the
radiotherapy-sensitization by hyperthermia, we compared the levels of HSP70 induction in
hyperthermia-sensitive and±resistant cell lines. The aim was to investigate, whether levels of
basal and inducible HSP70 could correlate with response rate to thermoradiotherapy in vitro.
Thermoradiotherapy in canine and human cancer cell lines
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Additionally, using the cancer cell lines grown without presence of any additional cell type
such as endothelial and immune cells (hence, excluding the effect of tumor microenviron-
ment), we wanted to investigate the effect of hyperthermia treatment on cancer cells alone, in
particular the effects on DNA damage and apoptosis/necrosis. In this context, we could study
the perfusion- and hypoxia-independent effects of hyperthermia treatment on cancer cells.
Moreover, little is known about response of the canine cancer cell lines to thermoradiotherapy
and how they compare to the human cancer. In particular, we focused canine sarcoma cell
lines, since inoperable or recurrent sarcoma is one of the disease entities for treatment with
hyperthermia in veterinary medicine [11, 12].
In our study, we used clonogenic cell survival assay and proliferation assay to assess the effi-
cacy of the combined thermoradiotherapy treatment, Comet assay to investigate the DNA
damage, apoptosis/necrosis assay to investigate the cell death, and we analyzed the HSP70 after
combined treatment by immunoblotting.
Material and methods
Cell lines
Human lung adenocarcinoma cell line A549 was a kind gift of Prof. Martin Pruschy (Univer-
sity Hospital Zurich, ZuÈrich, Switzerland). Canine soft tissues sarcoma (K9 STS) was a kind
gift of Prof. Marlene Hauck (NC State University, North Carolina, USA). Canine osteosarcoma
(UCDK9OSA17, Abrams, D17) and melanoma (UCDK9MM2) were kind gifts of Prof. Robert
Rebhun (University of California, Davis, California, USA). Canine transitional cell carcinoma
(K9 TCC) was a kind gift of Prof. Deborah Knapp (Purdue University, Indiana, USA). Human
osteosarcoma U2OS was a kind gift of Prof. Michael Hottiger (University of ZuÈrich, ZuÈrich,
Switzerland). A549 and K9 STS cells were maintained in RPMI 1640 cell culture media
medium supplemented with 10% FBS (Gibco), 1x GlutaMAX (Gibco), penicillin-streptomycin
(100 U/ml-100 μg/ml, Gibco), 1x non-essential amino-acids (Gibco), 1 mM sodium pyruvate
(Sigma) and 10 mM HEPES (Gibco). UCDK9OSA17, Abrams, D17, U20S, K9 TCC and
UCDK9MM2 were maintained in DMEM high glucose/pyruvate/L-glutamine cell culture
media (Invitrogen) supplemented with 10% FBS (Gibco), penicillin-streptomycin (100 U/ml-
100 μg/ml, Gibco) and 10 mM HEPES (Gibco). All cell lines used in the study were tested
mycoplasma-free.
Heating method and ionizing radiation
Control cells were maintained at 37ÊC in a humidified incubator with 5% CO2. Cells treated
with hyperthermia were incubated in the same type of humidified incubator from the start of
the heat-up phase, which took approximately 40 minutes. The subsequent hyperthermia treat-
ment at the target temperature (42ÊC) took another hour. Afterwards cells were removed from
the hyperthermia incubator and irradiated with 3 or 6 Gy (or as indicated in the figure legend).
In order to ensure that the cells are exposed to a repeatable temperature profile similar to what
we observe during in vivo treatments [12], we ran a series of thermometry measurements on
our incubator setup before starting with the treatment of cells. The temperature measured
directly (with a Bowman probe (SPEAG/IT'IS, Zurich, Switzerland)) in the cell culture dish is
provided in Fig 1 for three independent runs, along with the temperature shown on the incu-
bator's own temperature display. While the latter typically reaches the target temperature
within 25 minutes, the temperature in the dish is within 0.5ÊC of the target temperature after
less than 40 minutes. The incubator's specifications with respect to Uniformity and Tempera-
ture Control Fluctuation are ±0.25ÊC and ±0.1ÊC, respectively.
Thermoradiotherapy in canine and human cancer cell lines
PLOS ONE | https://doi.org/10.1371/journal.pone.0216744 May 15, 2019 3 / 15
Additionally, the time gap between hyperthermia and irradiation was between 10±20 min-
utes unless specified otherwise. Irradiation was performed with 6 MV linear accelerator
(Clinac iX, Varian, Palo Alto, USA), a field size of 30 × 30 cm, source-surface distance (SSD) of
100 cm, with a dose rate of 600 MU/min (= approximately 6 Gy/min). Control cells were
mock-irradiated.
Clonogenic cell survival assay
Clonogenic cell survival was determined in the cells treated with radiotherapy alone or com-
bined thermoradiotherapy. Cells were seeded into 10 cm petri-dishes the day before treatment
start (the cell number to reach optimal (separate single clones) number of clones was opti-
mized for every cell line and every condition beforehand: 0Gy/37ÊC/42ÊCÐ200 cells (A549,
Abrams, K9, TCC, MM2, OSA17), 250 cells (U2OS); 2Gy/37ÊC/42ÊCÐ250 cells (K9, MM2,
OSA17); 3Gy/37ÊC/42ÊCÐ400 cells (A549, TCC), 250 cells (Abrams) 1000 cells (U2OS); 4Gy/
37ÊC/42ÊCÐ500 cells (K9, MM2, OSA17); 6Gy/37ÊC/42±8000 cells (A549), 4000 cells (U2OS),
500 cells (Abrams), 1000 cells (K9, MM2, OSA17), 800 cells (TCC)). The following day, cells
were treated either with hyperthermia (42ÊC, heat-up plus 1 h) or control (37ÊC) and ionizing
radiation. After colony formation (depending on cell lines, approximately 10±14 days), colo-
nies were fixed (methanol/acetic acid; 3:1) and stained with crystal violet (1%, Sigma). Colo-
nies containing > 50 cells were counted manually using a colony counter. Cell-surviving
fraction was calculated by dividing the number of obtained colonies after treatment by the
number of seeded cells and correcting for plating efficiency of control cells.
Proliferation assay
The proliferative activity of tumor cells (A549) was assessed using Cell Counting kit-8 accord-
ing to the manufacturer protocol (Dojindo Molecular Technologies). Briefly, A549 cells were
Fig 1. Temperature profile of the incubator during heat-up phase to 42ÊC steady-state hyperthermia. Dots
represent temperature read off the incubator display over three independent runs, and lines represent the temperature
recorded by a sensor placed in the culture dish, immersed in medium during those same runs.
https://doi.org/10.1371/journal.pone.0216744.g001
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seeded in a 96-well plate the day before treatment start (500 cells/well). The following day cells
were treated with hyperthermia (42ÊC, heat-up plus 1 h) followed by ionizing radiation (6 Gy)
alone or combined treatment. The proliferation (OD at 450 and 600 nm) was measured 24, 48
and 72 hours after irradiation.
SDS-PAGE and immunoblotting
Cells were seeded (250'000±500'000) in a 10 cm dish the day before experiment start. The fol-
lowing day, cells were treated with hyperthermia (42ÊC, heat-up plus 1 h) followed by ionizing
radiation (6 Gy), protein lysates were collected 2 h after irradiation. Cells were lysed in RIPA
buffer (Sigma) with Protease Inhibitor Cocktail (Sigma). The protein concentration was
adjusted using BCA assay (Thermo Fisher Scientific). The samples were separated on a 4±15%
gradient gel (Bio-Rad) and blotted on PVDF membrane using a transfer apparatus according
to manufacturer's protocol (Bio-Rad). After blocking with 5% nonfat milk in TBST (Bio-Rad),
membranes were probed with the following antibodies: anti-HSP70 (C92F3A-5, 1:1000, Santa
Cruz and D69, 1:1000, Cell Signaling Technology (S2 Fig)), anti-Rad51 (D4B10, 1:1000, Cell
Signalling Technology), anti-HSP90 (ab13492, 1:1000, Abcam) anti beta-actin (8226, 1:1000,
Abcam); and secondary anti-mouse IgG, HRP-linked Antibody (#7076, 1:2000, Cell Signaling
Technology), and anti-rabbit IgG, HRP-linked Antibody (#7074, 1:1000, Cell Signaling Tech-
nology). The proteins were visualized using Pierce ECL Western Blotting Substrate (Thermo
Fisher Scientific) and exposed to x-ray film. The quantification of relative protein levels was
performed using Fiji software.
Transient transfection with siRNA
A549 cells were seeded in a 6-well plate at density of 100'000 cells/well the day before transfec-
tion. siRNA targeting HSP70 (sc-29352) was purchased from Santa Cruz Biotechnology. Con-
trol siRNA was purchased from Microsynth AG using the sequence described before [13].
Transfection with target and control siRNA (25 nM) was performed using TransIT-X2
Dynamic Delivery System (Mirus) according to the manufacturer protocol. Knockdown effi-
ciency was analyzed 48 h after transfection. To test the functional effect of HSP70 knockdown
on radiation sensitivity using clonogenic cell survival assay, cells were seeded for clonogenic
assay 24 h after transfection and treated with hyperthermia/radiation (as described above) 48 h
after transfection.
Comet assay
A549 cells (150'000 cells/well) were seeded in a 6-well plate the day before experiment start.
The following day, cells were treated with hyperthermia (heat-up plus 1 h, 42ÊC) or control
and irradiated with 8 Gy directly after hyperthermia treatment was finished. The cells were
trypsinized, counted and resuspended in PBS at a density of 200'000/ml. Afterwards 7.5 μL of
cell suspension were mixed with 65 μL of 1% low melting point agarose (LMPA, Trevigen, Gai-
thersburg, MA, USA) in PBS at 37ÊC.
Subsequently, 40 μL of agarose-cell solution was pipetted onto 2-well slides (Trevigen, Gai-
thersburg, MA, USA). The slides were then placed at 4ÊC for 10 min to allow agarose polymer-
ization. Subsequently, the slides were placed in lysis buffer (Trevigen, Gaithersburg, MA,
USA) for 90 min at 4ÊC in the dark. The slides were then incubated in the alkaline electropho-
resis solution (200 mM NaOH; 1 mM EDTA, pH 8.0) for 10 min at 4ÊC in the dark. The elec-
trophoresis was run at 300 mA for 30 min in an alkaline electrophoresis solution (200 mM
NaOH; 1 mM EDTA, pH 8.0). After electrophoresis, slides were washed twice with excess
H2O for 10 min at room temperature and incubated in 70% ethanol for 15 min at room
Thermoradiotherapy in canine and human cancer cell lines
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temperature. After drying (overnight), slides were stained in SybrGold solution 1:10'000 in TE
buffer, pH 8.0 for 15 min at room temperature, protected from light. The slides were washed
twice with H2O at room temperature and dried overnight. The COMET IV scoring system
was used to quantify the tail intensity (%DNA in tail) [14].
Apoptosis and necrosis assay
A549 cells were seeded in a white 96-well plate at a density of 5000/well. The following day,
cells were treated with hyperthermia (heat-up plus 1 h, 42ÊC) alone, radiation (6 Gy) alone or
combined thermoradiotherapy. 48 hours after treatment, cells were analyzed with RealTime-
Glo Annexin V Apoptosis and Necrosis Assay (Promega) multiplexed with CellTiter-Glo 2.0
Cell Viability Assay (Promega) to normalize for viable cell number according to the manufac-
turer's protocol.
Statistics
Statistical analyses were performed using R (The R Foundation for Statistical Computing, ver-
sion 3.5.0, 2018); the multicomp package (version 1.4±8) was used to conduct post-hoc tests.
To compare two groups two-tailed unpaired Student t-test was performed. Clonogenic cell
survival data was analyzed with ANOVA followed by Dunett's Multiple Comparison test to
compare treatment conditions to control. Linear-Quadratic (LQ) predictions were obtained
by fitting the equation log10(S) = - αD- βD2, α, β  0, where S represents the survival fraction
and D represents the dose. Enhancement factors (EF) of the α and β parameter estimates were
calculated by dividing the parameter estimates of the treatment (e.g. treatment with HT as
radiosensitizer) by the parameter estimates of the control (e.g. treatment with ionizing radia-
tion, but no HT). The remaining results were analyzed using mixed model ANOVA; a random
factor was used to model variation between experimental repetitions and Tukey's Multiple
Comparison Test was used to compare different groups to each other. P values are indicated in
the figures.
Results
Efficacy of thermoradiotherapy treatment in human and canine cancer cell
lines
We tested the effect of hyperthermia in the panel of human and canine cancer cell lines of dif-
ferent origin using clonogenic cell survival assay. While human A549 lung adenocarcinoma
cells and canine Abrams osteosarcoma cells were radiosensitized by pre-treatment with hyper-
thermia, all other cell lines did not show radiosensitization (Fig 2A±2H).
According to prior research, hyperthermia should increase the α parameter of LQ model by
an EF of 2 or even more while the β should remain relatively stable, i.e. β-EF  1[15]. For the
two cell lines subject to radiosensitization, this was the case. The U2OS also had an elevated α-
EF (1.6). Indeed, while not statistically significant, a radiosensitization effect is visible in the
plot. The large α-EF (7.9) of the UDCK9MM2 cell line is an artifact of very small α estimates.
Moreover, we tested if the single and combined treatments have an effect on A549 cells pro-
liferation over a 72 h period after treatment. Interestingly, hyperthermia alone treated cells
were proliferating faster than control at 24h time point but at later time points their prolifera-
tion was significantly reduced in comparison to control (S1 Fig). As expected, radiation and
combined thermoradiotherapy significantly inhibited A549 cell proliferation 48 and 72 h after
irradiation but there was no significant difference in cell proliferation between radiation/
Thermoradiotherapy in canine and human cancer cell lines
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hyperthermia alone and combined thermoradiotherapy treatment, e.g. no additive effect of
combined treatment (S1 Fig).
Different settings of hyperthermia treatment affect thermoradiotherapy
outcome
To further characterize the optimal settings for hyperthermia pre-treatment in vitro, we tested
different setup conditions of hyperthermia in A549 cell line and measured clonogenic cell sur-
vival. First, we tested if the time gap between hyperthermia and radiation plays a role in the
treatment outcome. Treatment with hyperthermia prior to irradiation significantly decreased
the clonogenicity of human lung adenocarcinoma cell line at 4 and 6 Gy, regardless of whether
the cells were irradiated 30 or 120 min after hyperthermia treatment (Fig 3A). The EF of the
LQ parameters reflect this observation; they are very similar for the 30 and for the 120 min
hyperthermia treatment. Next, we tested the three clinically relevant temperatures (41, 42 and
43ÊC, 1 h) in combination with radiation (Fig 3B). In this setting, pre-treatment with 41ÊC did
not show any effect (EF of the LQ parameters approximately 1), while pre-treating with 43ÊC
significantly reduced clonogenic cell survival in response to radiation. Correspondingly, the α-
Fig 2. Effect of thermoradiotherapy treatment on clonogenic cell survival of cancer cells. Clonogenic cell survival curves of human (A, B) and canine (C-H)
cancer cell lines. The corresponding LQ parameters along with their enhancement factors are given in a Table (I). Unpaired t-test. Mean of at least three
independent experiments ±SEM is shown.
https://doi.org/10.1371/journal.pone.0216744.g002
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EF for the 43ÊC treatment was the largest one (2.2) found for the A549 cell line in this work.
Subsequently, we tested the order of the treatments. Treatment with hyperthermia before radi-
ation was more efficiently inhibiting A549 cancer cell clonogenicity than treatment with radia-
tion first and then hyperthermia when compared to cells treated with radiation alone (Fig 3C).
As before, this is reflected in an increased α-EF for the case where hyperthermia was applied
before radiation.
DNA damage and apoptosis/necrosis after thermoradiotherapy treatment
As next step, we investigated the level of DNA damage in single and combined thermora-
diotherapy-treated A549 cells. The alkaline Comet assay was used as it can detect and quantify
effects of lower doses of radiation, more clinically relevant for our work. Radiation and com-
bined thermoradiotherapy significantly induced increase in tail lenght in comparison to con-
trol and hyperthermia alone-treated cells, however there was no significant difference between
radiation and combined thermoradiotherapy-treated cells (Fig 4A). Additionally, we tested
induction of apoptosis and necrosis levels by single and combined treatment 48 hours after
completion of the treatment. All three treatment-modalities (hyperthermia, radiation and
thermoradiotherapy) significantly induced apoptosis but not necrosis in comparison to con-
trol cells, however we did not observe additional enhancement when comparing thermora-
diotherapy to single hyperthermia/radiation treatment (Fig 4B and 4C).
Levels of HSP70 and Rad51 in hyperthermia-radiosensitized and -resistant
cell lines
To study the role of HSP70 in hyperthermia-treatment sensitivity, we measured the baseline
and thermoradiotherapy-induced HSP70 levels in eight cell lines shown in Fig 2. Interestingly,
Fig 3. Different conditions of hyperthermia pre-treatment affect radiation-sensitivity of A549 cells. Effect of the time gap between hyperthermia and
radiation on clonogenic cell survival (A). Influence of the hyperthermia temperature of 41, 42 and 43ÊC in combination with radiation on A549 clonogenic cell
survival (B). Treatment with hyperthermia (42ÊC, 1 h) first versus radiation first affects clonogenic cell survival of A549 cells (C). One-way ANOVA with
Dunnett's multiple comparison test. Mean of at least three independent experiments ±SEM is shown.
https://doi.org/10.1371/journal.pone.0216744.g003
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only A549 had high baseline levels of HSP70, which were further induced upon thermora-
diotherapy treatment (Fig 5A and 5B). The remaining seven cell lines had very low or not
detectable HSP70 levels in comparison to A549 in untreated cells with strong induction upon
thermoradiotherapy treatment. We have also analyzed levels of Rad51 protein upon thermora-
diotherapy treatment which were unaffected in all cell lines tested (Fig 5A and 5B).
Effect of HSP70 Knockdown on thermoradiotherapy outcome
To further investigate the role of heat shock proteins in thermoradiotherapy-treatment
response, we generated transient knockdown of HSP70 in A549 cells. In contrary to HSP70,
HSP90 was not induced by hyperthermia alone in A549 cells (S2 Fig), therefore we generated
knockdown of HSP70 to study its role in thermoradiosensitization. HSP70 knockdown cells
and siControl-transfected cells were treated with radiotherapy alone or combined thermora-
diotherapy 48 h after transfection and plated for analysis of clonogenic cell survival.Knock-
down efficiency was confirmed by immunoblotting (Fig 6A). Interestingly, transient
knockdown of HSP70 did not result in further decrease of clonogenic cell survival in response
to radiotherapy alone and thermoradiotherapy when compared to control cells (Fig 6B). The
radiosensitizing effect of hyperthermia yields and enhancement for the α parameter (2.0, 3.3)
while the β parameter largely remains unchanged (β-EF  1).
Discussion
Hyperthermia is mostly an experimental treatment modality used to sensitize tumors to radio-
therapy in human and veterinary oncology, only a small number of centers is applying HT-RT
in clinical routine for some specific indications (bladder, breast wall recurrence of mammary
carcinoma) [12, 16]. In order to exclude the effects of the tumor microenvironment and focus
on cancer cell response alone, we deliberately tested the effect of thermoradiotherapy treat-
ment on a panel of human as well as canine cancer cell lines in vitro. Human cell lines A549
and U2OS were used for comparison, A549 as a `positive' control cell line for hyperthermia as
its sensitivity to it was shown before [17]. Interestingly, the majority of the canine cancer cell
lines were not sensitized by hyperthermia. The effect of hyperthermia on sensitization of
tumor is observed mainly in vivo, indicating that the tumor microenvironment is necessary for
Fig 4. Analysis of DNA damage and apoptosis/necrosis in hyperthermia, radiation and combined thermoradiotherapy-treated A549 cells. DNA damage
(tail intensity analyzed by Comet assay) in A549 cells (A). Apoptosis (B) and necrosis (C) in A549 cells 48 h after treatment. Luminescent/fluorescent signal
intensity values were normalized by the number of cells (coupled luminescence assay) in each well. Mixed model ANOVA with Tukey's multiple comparison
test. Mean of three independent experiments ±SEM is shown.
https://doi.org/10.1371/journal.pone.0216744.g004
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the radiosensitizing effect of hyperthermia. Increased tumor perfusion and decreased hypoxia
are the major contributors to increased radiosensitization in vivo. However, hyperthermia can
sensitize cells growing in vitro by potentially affecting DNA repair and in vivo due to an addi-
tional effect on the microenvironment. Additionally, immunomodulatory effects of HSPs
induced upon hyperthermia treatment also contribute to treatment response [7]. None of
these factors is present in the in vitro setting, when cancer cell lines are grown in 2D cultures.
Fig 5. Levels of HSP70 and Rad51 in control and thermoradiotherapy-treated human and canine cancer cell lines. Cell lysates analyzed by
immunoblotting for HSP70 and Rad51 and β-actin in control (-) and thermoradiotherapy (+; (42ÊC, heat-up plus 1 h) followed by ionizing radiation (6 Gy))-
treated cells (A). Representative experiment of three experiments performed independently is shown. Quantification of HSP70 and Rad51 immunoblot signal
normalized to β-actin (B). Mean of three independent experiments ±SEM is shown.
https://doi.org/10.1371/journal.pone.0216744.g005
Thermoradiotherapy in canine and human cancer cell lines
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Not surprisingly, we observed radiosensitizing effects of hyperthermia in only two out of eight
cell lines tested. The majority of sarcoma/osteosarcoma cell lines (the tumor type commonly
treated with hyperthermia in the veterinary clinic) was resistant to hyperthermia treatment in
vitro, e.g. on the pure cellular level [11]. We chose a treatment at 42ÊC for a time period of 1
hour to screen different cell lines for their thermoradiotherapy-sensitivity as this is the most
clinically relevant temperature, and as it does not have a strong cytotoxic effect on cancer cells
alone. A previous study showed various degrees of cell cytotoxicity at 42ÊC, van den Tempel
et al. found decreasing cell survival in response to thermoradiotherapy in the temperatures
above 41ÊC and the degree of decrease was dependent on the cell line and duration of the
hyperthermia pre-treatment in different human cancer cell lines: BLM, HeLa, FaDu and
VH10-SV40 [18]. As predicted, we observed no radiosensitization at 41ÊC and the strongest
decrease in clonogenic survival at 43ÊC. In our study, the time gap between hyperthermia
treatment and radiation (30 min versus 120 min) appeared to have no effect on the cell sur-
vival. This is in line with previous reports, where the radiosensitizing effect of hyperthermia
was maintained even for up to several hours after hyperthermia treatment in cervical carci-
noma cell lines [19]. It is, however, not in line with reports where the best effect was observed
or predicted with a short time-gap in vitro [20, 21], and in vivo [22, 23]. Treatment with hyper-
thermia before radiation was more effective than the opposite setup, which has also recently
been shown in fibrosarcoma tumor xenografts [24]. This setting is especially valid in vivo, as
Fig 6. HSP70 knockdown in A549 cells. Efficiency of HSP70 downregulation 48 h after transfection in A549 cells; immunoblot (upper panel) and relative
quantification of HSP70 normalized to β-actin (lower panel) and normalized to non-transfected cells, mean of three independent experiments ±SEM is shown
(A). Effect of HSP70 knockdown on clonogenic cell survival of A549 cells treated with radiation or combined thermoradiotherapy (B). A control siRNA (siCtrl)
was used versus HSP70-KD cells. The corresponding LQ parameters along with their enhancement factors are given in a table (lower panel). Unpaired t-test.
https://doi.org/10.1371/journal.pone.0216744.g006
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pre-treatment with hyperthermia can lead to increased perfusion, followed by reoxygenation
and resulting radiosensitization. Interestingly, we could observe it also in vitro, which suggests
that there are intracellular pathways being activated in response to hyperthermia that render
the cells more radiosensitive. One of the radiosensitizing effects of hyperthermia could be
potentially attributed to decrease in DNA damage repair after thermoradiotherapy treatment
and/or increased DNA damage. However, we could not detect increased DNA damage as mea-
sured by Comet assay in response to hyperthermia alone. Possibly, the clinically-relevant dose
of 6Gy is already inducing the high amount DNA damage (saturated signal) and further
increase by hyperthermia cannot be measured in this setting. As predicted, radiation alone
and thermoradiotherapy induced increased formation of DNA breaks in A549 cells but there
was no additional increase in DNA damage upon thermoradiotherapy treatment in compari-
son to radiation alone. It could also suggest that thermoradiotherapy treatment does not
increase the number of inflicted DNA damage but rather could affect the DNA repair pathway
[25]. Indeed, it has been shown recently, that hyperthermia-treated cells and tumors have
decreased levels of BRCA2 protein [18, 26]. Moreover, it has been shown that mild hyperther-
mia inhibits homologous recombination and induces BRCA2 degradation [27].
Levels of HSP70 protein are induced in many types of malignancies. Our observation
showed that only A549 had high baseline levels of HSP70 in comparison to other cell lines
tested, another hyperthermia-sensitized cell line Abrams had low baseline levels. However, all
cell lines showed strong induction upon thermoradiotherapy treatment, which suggests that
the baseline and induced levels of HSP70 may not be sufficient to predict the response to ther-
moradiotherapy treatment in vitro. Moreover, we analyzed levels of Rad51 protein in cells
exposed to thermoradiotherapy. It was previously shown that radiation induced Rad51 foci are
transiently inhibited by hyperthermia and localization and size of Rad51 foci was affected by
the thermal dose [18, 28]. However, we did not observe differences in Rad51 protein levels
analyzed by immunoblotting in any of the cell lines analyzed.
We observed no beneficial effect of knockdown of HSP70 on (thermo)radiosensitivity of
A549 cells. Murakami et al., showed that mouse mammary carcinoma cell line 4T1 with low
cytosolic and membrane-bound HSP70 was significantly more radiation-sensitive than control
cells [29]. Moreover, human colon adenocarcinoma CX+ with a stable high membrane-bound
HSP70 (mHSP70) was significantly more radiation-resistant that CX- with stable low levels of
mHSP70; interestingly, CX+ and CX- have equal levels of cytosolic HSP70, which suggests that
mHSP70 and not cytosolic HSP70 is responsible for radiation sensitivity [29]. In the same
study, no significant differences in radiation sensitivity in H1339 and EPLC-272H lung carci-
noma cells with heat shock factor-1 (HSF-1) knockdown versus control were observed, which
have significant differences in cytosolic but not mHSP70 levels [29]. Since in our study we
only analyzed the cytosolic levels of HSP70 in A549 upon knockdown, which were decreased
in comparison to control cells, it might explain the lack of (thermo)radiosensitization of A549
when only cytosolic HSP70 levels are reduced. Furthermore, Vriend et al. and Krawczyk et al.
previously showed in their work that inhibiting HSP90 increased radiation sensitivity of vari-
ous cell lines [27, 30]. We chose to focus on HSP70 as we observed it was modulated by heat in
our cell lines.
Regarding the applied method for hyperthermia, we used a direct heat CO2 regular incuba-
tor, since it shows a similar temperature profile to the hyperthermia applicator used for clinical
treatments. Our aim in this study was not to achieve the fastest heat-up possible, but rather to
put effort into establishing conditions that are similar to what we have during patient treat-
ment. Our measurement rules out an excessively slow heat-up phase in which the target tem-
perature would never have been reached. Additionally, we want to point out that our
measurements include potential effects of evaporative cooling since we measured the liquid
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directly. Moreover, we considered the potential influence of thermotolerance, a phenomenon
where cells continue to function normally after pre-exposure to high temperature, and which
is attributed to increased HSPs [31±34]. We consider our method of heating not to induce
thermotolerance, however this concern should be further investigated as it could reduce the
sensitivity of cells towards radiation.
In conclusion, we showed that hyperthermia has limited potency to radiosensitize canine
cancer cells grown in a 2D cell culture setting used in our study. Tumor cell-type, temperature
and order of the treatment play are relevant factors in inducing radiosensitization by hyper-
thermia. Moreover, the majority of the cell lines used in our study are of mesenchymal origin,
which could be be the reason of their intrinsic radioresistance. We did not observe increased
DNA damage and apoptosis/necrosis upon combined treatment in comparison to single
radiotherapy/hyperthermia treatment. We chose a 48 hours time point as previous studies
showed that apoptosis and necrosis are induced by radiation and hyperthermia from that time
[35, 36]. However, the changes might be observed at later time points, not analyzed here.
Moreover, cytosolic levels of HSP70 alone appear not to play critical role in the hyperthermia-
radiosensitization of lung adenocarcinoma cell line A549. Possibly, the membrane form of
HSP70 is more critically involved in the radiosensitization mechanism. Further studies in dif-
ferent cell lines are required to analyze this issue.
Supporting information
S1 Fig. Proliferation of A549 cells in response to single and combined thermoradiotherapy
analyzed at 24, 48 and 72 h after treatment. Mixed model ANOVA with Tukey's multiple
comparison test. Mean of three independent experiments ±SEM is shown.
(TIF)
S2 Fig. Levels of HSP70 and HSP90 in response to heat in A549 cells. Cell lysates were col-
lected before, during heat-up phase, during hyperthermia treatment (42ÊC, 1h) and at indi-
cated time-point after treatment. Representative experiment of three experiments performed
independently is shown.
(TIF)
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